Do you have non-alcoholic fatty liver disease (NAFLD)?
NAFLD is a condition where there is an accumulation of fatty cells in the liver. One kind of liver cancer, hepatocellular carcinoma (HCC), is increasing more rapidly than any other cancer in the United States., due mainly to an increase in the prevalence of NAFLD. NAFLD affects about 25% of the general population worldwide, and it is the most common cause of chronic liver disease and cirrhosis
Role of lisinopril in preventing the progression of non-alcoholic fatty liver disease
Principal Investigator: Dr. Mazen Noureddin
Cedars-Sinai Medical Center
This study will test the effects of lisinopril on people’s risk of developing hepatocellular carcinoma (HCC). Lisinopril is a medication that has been commonly used to treat high blood pressure since 1987 in the U.S. Participants in this study will receive 10 mg of lisinopril orally once daily for up to 24 weeks, in addition to their standard of care. This will allow researchers to see if participants taking lisinopril show changes in their liver, which may indicate a lower risk of developing cancer.
This study will soon be looking for volunteers who are 18 years of age or older and have NAFLD. We will enroll 40 participants.
You may be eligible if you:
Have a higher than average risk of developing liver cancer due to your diagnosis of NAFLD
Have advanced fibrosis (scarring)
If you think you may be eligible, look for more information here soon. Study locations are:
Cedars-Sinai Medical Center– Los Angeles, California
Duke University - Durham, North Carolina
Mount Sinai Health System - New York, New York